Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Elashoff

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Cancer|June 3, 2015
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancerKaren L Reckamp, Marianna Koczywas, Mihaela C Cristea, et al.
The American Journal of Cardiology|April 13, 2016
Acute Effect of Hookah Smoking on the Human Coronary MicrocirculationMichael D Nelson, Mary Rezk-Hanna, Florian Rader, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Archives of Neurology|May 16, 2007
Testosterone treatment in multiple sclerosis: a pilot studyNancy L Sicotte, Barbara S Giesser, Vinita Tandon, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 21, 2019
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung DiseaseGrace Hyun J Kim, Donald P Tashkin, Pechin Lo, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomasVladimir Evilevitch, Wolfgang A Weber, William D Tap, et al.
OBM Transplantation|August 16, 2019
The Impact of Allograft CXCL9 during Respiratory Infection on the Risk of Chronic Lung Allograft DysfunctionMichael Y Shino, Ariss DerHovanessian, David M Sayah, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Cancer|June 3, 2015
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancerKaren L Reckamp, Marianna Koczywas, Mihaela C Cristea, et al.
The American Journal of Cardiology|April 13, 2016
Acute Effect of Hookah Smoking on the Human Coronary MicrocirculationMichael D Nelson, Mary Rezk-Hanna, Florian Rader, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Archives of Neurology|May 16, 2007
Testosterone treatment in multiple sclerosis: a pilot studyNancy L Sicotte, Barbara S Giesser, Vinita Tandon, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 21, 2019
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung DiseaseGrace Hyun J Kim, Donald P Tashkin, Pechin Lo, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomasVladimir Evilevitch, Wolfgang A Weber, William D Tap, et al.
OBM Transplantation|August 16, 2019
The Impact of Allograft CXCL9 during Respiratory Infection on the Risk of Chronic Lung Allograft DysfunctionMichael Y Shino, Ariss DerHovanessian, David M Sayah, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Pageof 15